WHAT IS CLAIMED IS:

1   1.   A compound having the formula:

2                         $Ab\text{—}G\text{–}L\text{—}T$

3   wherein

4   Ab is an antibody;

5   G is an intact glycosyl linking group covalently joining Ab to L;

6   L is a bond or a spacer moiety covalently joining G to T; and

7   T is a toxin.

1   2.   The compound according to claim 1, wherein said linker moiety is a

2 member selected from substituted or unsubstituted alkyl, substituted or unsubstituted

3 heteroalkyl and substituted or unsubstituted aryl moieties.

1   3.   The compound according to claim 2, wherein said linker moiety

2 comprises a poly(ethylene glycol) moiety.

1   4.   The compound according to claim 1, wherein L has the formula:

2                    $\xi\text{—}L^{1}\text{—}A\text{–}L^{2}\text{–}\xi$

3   wherein

4   L^{1} is a bond or a linker moiety covalently joining S to A;

5   A is an amplifier moiety; and

6   L^{2} is a bond or a spacer moiety covalently adjoining A to T.

1   5.   The compound according to claim 4, wherein said amplifier moiety is a

2 polyamine moiety.

1   6.   The compound according to claim 5, wherein said polyamine moiety is

2 a dendrimer.

1   7.   The compound according to claim 4, having the formula:

2                $Ab\text{–}G\text{——}(PEG)_{m}\text{-}(toxin)_{n}$

3   wherein

4   PEG is a straight- or branched-chain poly(ethylene glycol);

5   m is an integer from 1 to 6; and

6   n is an integer from 1 to 1,000.

1   8.   The compound according to claim 4, having the formula:

2                  $Ab-G-L^1-(dendrimer)_m-(L^2-toxin)_n$

3 wherein

4   m is an integer from 1 to 6; and

5   n is an integer from 1 to 1,000.

1   9.   The compound according to claim 4, having the formula:

2                  $Ab-G-(L^1)_m-(toxin)_n$

3 wherein

4   m is an integer from 1 to 6; and

5   n is an integer from 1 to 1,000.

1   10.   The compound according to claim 1, having the formula:

$$Ab-G-X^1-PEG-X^2-A\left(X^3-(CH_2)_a-Z-(CH_2)_b-X^4-T\right)_n$$

2

3 wherein

4   X^1, X^2 and X^4 are linking groups and are members selected from the group

5   consisting of O, S, NH, $(CH_2)_q$-NH, NH-$(CH_2)_q$, NH-C(O)-O,

6   O-C(O)-NH, $(CH_2)_q$-NH-C(O)-O, O-C(O)-NH-$(CH_2)_q$, C(O)-O,

7   O-C(O), $(CH_2)_q$-NH-C(O), C(O)-NH-$(CH_2)_q$, NH-C(S), and C(S)-NH

8   and wherein

9   A is an amplifier moiety;

10   Z is a bond cleaved by a metabolic/physiological process;

11   n is an integer from 1 to 1,000;

12   a is an integer from 1 to 10;

13   b is an integer from 1 to 10; and

14   q is and integer from 0 to 20.

1   11.   The compound according to claim 1, having the formula:

$$Ab-G-X^1-PEG-X^2-A-\begin{matrix}R^5 \\ | \\ \diamondsuit O \\ R^4 \quad R^3 \quad R^2 \end{matrix}R^1$$

2

3 wherein

4   at least one of R^1, R^2, R^3, R^4, R^5, is :

$$\xi\!-\!X^1\!-\!\underset{\underset{O}{\|}}{C}\!-\!X^2\!-\!(CH_2CH_2O)_r\!-\!CH_2CH_2\!-\!X^3\!-\!T$$

5

6   wherein

7   r is an integer from 1 to 2,500;

8   Z^1 is selected from the group consisting of O, S, and NH;

9 Z^2 is selected from the group consisting of NH, and $NH\text{-}(CH_2)_q$;

10   and

11   X^1, X^2 and X^3 are linking groups and are members selected from the group

12   consisting of O, S, NH, $(CH_2)_q\text{-}NH$, $NH\text{-}(CH_2)_q$, $NH\text{-}C(O)\text{-}O$,

13             $O\text{-}C(O)\text{-}NH$, $(CH_2)_q\text{-}NH\text{-}C(O)\text{-}O$, $O\text{-}C(O)\text{-}NH\text{-}(CH_2)_q$, $C(O)\text{-}O$,

14             $O\text{-}C(O)$, $(CH_2)_q\text{-}NH\text{-}C(O)$, $C(O)\text{-}NH\text{-}(CH_2)_q$, $NH\text{-}C(S)$, and $C(S)\text{-}NH$

15   wherein

16   n is an integer from 1 to 1,000; and

17   q is an integer from 0 to 20.

1   12.   The compound according to claim **1**, having the formula:

2

3   wherein

4   X^1, X^2 and X^4 are linking groups and are members selected from the group

5   consisting of O, S, NH, $(CH_2)_q\text{-}NH$, $NH\text{-}(CH_2)_q$, $NH\text{-}C(O)\text{-}O$,

6            $O\text{-}C(O)\text{-}NH$, $(CH_2)_q\text{-}NH\text{-}C(O)\text{-}O$, $O\text{-}C(O)\text{-}NH\text{-}(CH_2)_q$, $C(O)\text{-}O$,

7            $O\text{-}C(O)$, $(CH_2)_q\text{-}NH\text{-}C(O)$, $C(O)\text{-}NH\text{-}(CH_2)_q$, $NH\text{-}C(S)$, and $C(S)\text{-}NH$

8   wherein

9   n is an integer from 1 to 1,000; and

10   q is an integer from 0 to 20.

1   13.   The compound according to claim 12, having the formula:

2

1   14.   A compound having the formula:

2   S—L—T

3   wherein

4   S is a nucleotide sugar

5   L is a bond or a spacer moiety covalently joining S to T; and

6   T is a toxin moiety.

1   15.   The compound according to claim 14, wherein said spacer moiety is a

2   member selected from substituted or unsubstituted alkyl, substituted or unsubstituted

3   heteroalkyl and substituted or unsubstituted aryl moieties.

1   16.   The compound according to claim 15, wherein said spacer moiety

2   comprises a poly(ethylene glycol) moiety.

1   17.   The compound according to claim 14, wherein L has the formula:

2   ξ—L^1—A—L^2—ξ

3   wherein

4   L^1 is a bond or a spacer moiety covalently joining S to A;

5   A is an amplifier moiety; and

6   L^2 is a bond or a spacer moiety covalently joining A to T.

1   18.   The compound according to claim 17, wherein said amplifier moiety is

2   a polyamine moiety.

1   19.   The compound according to claim 18, wherein said polyamine moiety

2   is a dendrimer.

1   20.   The compound according to claim 17, having the formula:

2   S—$(PEG)_m$-$(toxin)_n$

3   wherein

4   PEG is a straight- or branched-chain poly(ethylene glycol);

5   m is an integer from 1 to 6; and

6   n is an integer from 1 to 1,000.

1   21.   The compound according to claim 17, having the formula:

2   S—L^1–$(dendrimer)_m$-$(L^2$-$toxin)_n$

3   wherein

4   m is an integer from 1 to 6; and

5   n is an integer from 1 to 1,000.

1   22.   The compound according to claim 17, having the formula:

2    $$S-(L^1)_m-(toxin)_n$$

3   wherein

4   m is an integer from 1 to 6; and

5   n is an integer from 1 to 1,000.

1   23.   The compound according to claim 22, having the formula:

$$Sugar-X^1-PEG-X^2-A \left(X^3-(CH_2)_a-Z-(CH_2)_b-X^4-T \right)_n$$

2

3   wherein

4   X^1, X^2 and X^3 are linking groups and are members selected from the group

5   consisting of O, S, $NH(CH_2)_q$-NH, $NH-(CH_2)_q$, NH-C(O)-O,

6   O-C(O)-NH, $(CH_2)_q$-NH-C(O)-O, $O-C(O)-NH-(CH_2)_q$, C(O)-O,

7   O-C(O), $(CH_2)_q$-NH-C(O), $C(O)-NH-(CH_2)_q$, NH-C(S), and C(S)-NH

8   and wherein

9   A is an amplifier moiety;

10   Z is a bond cleaved by a metabolic/physiological process;

11   n is an integer from 1 to 1,000;

12   a is an integer from 1 to 10;

13   b is an integer from 1 to 10; and

14   q is and integer from 0 to 20.

1   24.   The compound according to claim 14, having the formula:

$$Sugar-X^1-PEG-X^2-A \left(NH \underset{O}{\overset{O}{C}} -S-S- \underset{O}{\overset{O}{C}} X^3-T \right)_n$$

2

3   wherein

4   X^1, X^2 and X^3 are linking groups and are members selected from the group

5   consisting of O, S, $NH(CH_2)_q$-NH, $NH-(CH_2)_q$, NH-C(O)-O,

6   O-C(O)-NH, $(CH_2)_q$-NH-C(O)-O, O-C(O)-NH-$(CH_2)_q$, C(O)-O,

7   O-C(O), $(CH_2)_q$-NH-C(O), C(O)-NH-$(CH_2)_q$, NH-C(S), and C(S)-NH

8   wherein

9   q is an integer from 0 to 20.

1   25.   The compound according to claim 24, having the formula:

2